A recent study compared two dosages of ifinatamab deruxtecan among patients with extensive-stage small cell lung cancer.
ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.
Zacks.com on MSN3d
Study: Merck and Daiichi's Lung Cancer Treatment Shows PromiseMRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in ...
Patritumab deruxtecan (HER3-DXd), a HER3 directed ADC, ifinatamab deruxtecan (I-DXd), a B7-H3 directed ADC, and raludotatug deruxtecan (R-DXd), a CDH6 directed ADC, are being jointly developed and ...
Initial results from dose escalation in the first in-human phase 1 trial of DS-9606 suggest early promising clinical activity in patients with advanced solid tumours known to express Claudin-6 (CLDN6) ...
MSD and Daiichi Sankyo have revealed some of the clinical data that prompted them to start pivotal testing of ifinatamab deruxtecan (I-DXd) in patients with previously treated, extensive-stage ...
Daiichi Sankyo and MSD (Merck & Co) have reported that the Phase III HERTHENA-Lung02 clinical trial of patritumab deruxtecan, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback